TriOar signs $356 million technology transfer agreement with Celltrion

CAR-T Digest - August 2020

19 November 2025: TriOar signs $356 million technology transfer agreement with Celltrion

TriOar entered a major partnership with Celltrion, signing a technology transfer and joint development deal for its TROCAD platform, potentially worth up to $356 million across development and sales milestones
TROCAD, TriOar’s conditionally activatable ADC technology, is designed to deliver cancer drugs more precisely by blocking unwanted binding to normal cells, improving both efficacy and safety
With this agreement, Celltrion can use the TROCAD platform to develop and commercialize up to six ADC programs, positioning it to expand its oncology pipeline
Two of these targets include an option for joint development, which would allow both companies to share deeper technical know-how and co-advance next-generation ADC technologies.
TriOar highlighted that the deal signals global recognition of its platform’s competitiveness, with both companies planning to broaden their collaboration in innovative drug development